Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SMMT Summit Therapeutics PLC

休市中 10-16 16:00:00 EDT

14.63

-0.74

-4.81%

盘后14.55

-0.08-0.54%

19:58 EDT

最高15.41	最低14.56	成交量433.10万
今开15.39	昨收15.37	日振幅5.53%
总市值116.71亿	流通市值22.58亿	总股本7.98亿
成交额6,410万	换手率2.81%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":14.63,"timestamp":1792180800000,"preClose":15.37,"halted":0,"volume":4331009,"hourTrading":{"tag":"盘后","latestPrice":14.5505,"preClose":14.63,"latestTime":"19:58 EDT","volume":68446,"amount":1000721.2635,"timestamp":1792195127474,"change":-0.0795,"changeRate":-0.005434,"amplitude":0.012987},"delay":0,"changeRate":-0.048145738451528856,"floatShares":154320004,"shares":797749602,"eps":-1.117703,"marketStatus":"休市中","change":-0.74,"latestTime":"10-16 16:00:00 EDT","open":15.39,"high":15.41,"low":14.56,"amount":64097451.994922005,"amplitude":0.055303,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.117703,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":15.37,"preHourTrading":{"tag":"盘前","latestPrice":15.35,"preClose":15.37,"latestTime":"09:22 EDT","volume":8377,"amount":129141.071796,"timestamp":1792156926835,"change":-0.02,"changeRate":-0.001301,"amplitude":0.009759},"postHourTrading":{"tag":"盘后","latestPrice":14.5505,"preClose":14.63,"latestTime":"19:58 EDT","volume":68446,"amount":1000721.2635,"timestamp":1792195127474,"change":-0.0795,"changeRate":-0.005434,"amplitude":0.012987},"volumeRatio":0.8123234709948519,"impliedVol":1.3821,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"1133353921","title":"异动解读｜Summit Therapeutics盘中下跌5.01%，阿斯利康20亿美元战略投资落地后抛压延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1133353921","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133353921?lang=zh_cn&edition=full","pubTime":"2026-10-17 03:45","pubTimestamp":1792179905,"startTime":"0","endTime":"0","summary":"10月17日，Summit Therapeutics盘中下跌5.01%，报14.6美元/股，成交额4843.94万美元。消息面上，公司此前披露阿斯利康已完成20亿美元战略股权投资，购入可转换优先股；同时三方正推进Datroway与ivonescimab联用，拟率先开展一线三阴性乳腺癌Ⅲ期试验。此次资金到位有助于缓解公司此前现金不足压力，并强化核心肿瘤管线推进，但在前期利好兑现后，股价短线仍出现波动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"阿斯利康20亿注资后，Summit股价承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105656734","title":"异动解读｜Summit Therapeutics盘中下跌5.08%，阿斯利康20亿美元战略投资完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1105656734","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105656734?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:48","pubTimestamp":1791899335,"startTime":"0","endTime":"0","summary":"10月13日，Summit Therapeutics盘中下跌5.08%，报16.26美元/股，成交额1197.29万美元。消息面上，公司此前披露阿斯利康已完成对其20亿美元战略股权投资，购买可转换优先股；双方还围绕ivonescimab及相关肿瘤药物组合推进临床合作。进一步看，三方近期还宣布将把Datroway与ivonescimab联用，率先启动一项用于一线三阴性乳腺癌的Ⅲ期试验。此次资金到位有助于缓解公司此前现金压力，并强化其核心肿瘤管线推进能力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Summit股价下跌，阿斯利康20亿美元投资到位","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126633039","title":"异动解读｜Summit Therapeutics盘中下跌5.13%，阿斯利康合作利好消化后回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1126633039","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126633039?lang=zh_cn&edition=full","pubTime":"2026-10-08 21:46","pubTimestamp":1791467213,"startTime":"0","endTime":"0","summary":"10月8日，Summit Therapeutics盘中下跌5.13%，报17.03美元/股，成交额1012.02万美元。该股在阿斯利康完成20亿美元战略股权投资及联合疗法合作消息推动连续上涨后，出现获利回吐。消息面上，阿斯利康已于此前完成对Summit的20亿美元战略股权投资，购买108,955股可转换优先股，双方将合作评估ivonescimab与阿斯利康旗下多种抗癌药物的联合疗效。背景上，Summit Therapeutics核心候选药物ivonescimab近期在多项III期临床试验中展现积极总生存期数据，公司管线估值获市场重估。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190246223","title":"异动解读｜Summit Therapeutics盘中上涨5.23%，阿斯利康20亿美元投资与联合疗法合作提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1190246223","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190246223?lang=zh_cn&edition=full","pubTime":"2026-10-07 22:44","pubTimestamp":1791384278,"startTime":"0","endTime":"0","summary":"10月7日，Summit Therapeutics盘中上涨5.23%，报18.215美元/股，成交额4550.39万美元。股价走强主要受到阿斯利康完成20亿美元战略股权投资以及双方癌症药物组合试验合作推进的提振。根据协议，阿斯利康购买108,955股可转换优先股，并将与Summit共同评估其核心候选药物ivonescimab与阿斯利康旗下多种抗癌药物的联合疗效，研究计划由阿斯利康主导并分担成本。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康20亿美元入股，Summit股价大涨","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183480703","title":"异动解读｜Summit Therapeutics盘中上涨5.1%，阿斯利康完成20亿美元股权投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1183480703","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183480703?lang=zh_cn&edition=full","pubTime":"2026-10-06 01:50","pubTimestamp":1791222651,"startTime":"0","endTime":"0","summary":"10月6日，Summit Therapeutics盘中上涨5.1%，报17.61美元/股，成交额5051.68万美元。消息面上，阿斯利康完成对Summit Therapeutics的20亿美元战略股权投资。根据协议，阿斯利康购买108,955股可转换优先股，双方将合作测试ivonescimab等癌症药物组合的疗效。Summit Therapeutics是一家专注于肿瘤治疗领域药物开发的生物制药公司，致力于发现、开发和商业化患者友好的新一代标准疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Summit Therapeutics股价上涨，阿斯利康完成20亿美元投资","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673774823","title":"起亚今年前八月英国销量位居第二，仅次于大众","url":"https://stock-news.laohu8.com/highlight/detail?id=2673774823","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673774823?lang=zh_cn&edition=full","pubTime":"2026-10-05 10:33","pubTimestamp":1791167625,"startTime":"0","endTime":"0","summary":"周一公布的行业数据显示，起亚汽车今年前8个月在英国的销量位居第二，得益于旗下Sportage运动型多用途车的强劲需求。数据显示，起亚排名第二，仅次于销量为111830辆的大众汽车。起亚在英国的销量稳步增长，已连续四年突破10万辆大关。今年，起亚Sportage车型在英国单一车型销量榜上排名第二，销量为30，564辆，仅次于销量为35，968辆的福特Puma。Sportage约占起亚今年迄今在英国总销量的40%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-05/doc-iniucuem4619678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU2488822045.USD","SMMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117420110","title":"异动解读｜Summit Therapeutics盘中上涨5.03%，阿斯利康20亿美元投资持续提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1117420110","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117420110?lang=zh_cn&edition=full","pubTime":"2026-09-30 22:54","pubTimestamp":1790780077,"startTime":"0","endTime":"0","summary":"9月30日，Summit Therapeutics盘中上涨5.03%，报17.215美元/股，成交额5757.47万美元。英国制药巨头阿斯利康于9月29日宣布向Summit投资20亿美元可转换优先股，并达成一项围绕依沃西单抗及sonesitatug vedotin的非约束性临床合作协议。双方计划评估依沃西单抗与阿斯利康旗下多款癌症药物的联合疗法，研究费用共同承担，临床试验拟由阿斯利康发起。小摩与花旗均对此投资表示看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康20亿投资加持，Summit股价强势上涨","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671223551","title":"英国8月份汽车产量增长5.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671223551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671223551?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:30","pubTimestamp":1790724600,"startTime":"0","endTime":"0","summary":"周三公布的行业数据显示，受国内汽车需求回升带动，英国8月份汽车产量出现反弹；不过，欧盟贸易争端的加剧可能会对该行业的长期前景构成压力。英国汽车制造商与贸易商协会表示，8月份英国汽车产量增长5.7%，达到40，872辆。通常情况下，由于工厂按计划停产，8月份往往呈现产量低且波动大的特点。英国汽车制造商与贸易商协会表示，迈凯伦、日产和宾利等企业投入的逾10亿英镑资金，是汽车制造业长期前景良好的重要风向标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-30/doc-initqefr2548195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134725250","title":"异动解读｜Summit Therapeutics盘中上涨18.98%，阿斯利康20亿美元投资加码依沃西单抗合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1134725250","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134725250?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:32","pubTimestamp":1790688757,"startTime":"0","endTime":"0","summary":"9月29日，Summit Therapeutics盘中上涨18.98%，报17.95美元/股，成交额7665.23万美元。消息面上，英国制药巨头阿斯利康宣布向Summit投资20亿美元可转换优先股，并达成一项围绕依沃西单抗及sonesitatug vedotin的非约束性临床合作协议。双方计划评估依沃西单抗与阿斯利康旗下多款癌症药物的联合疗法，研究费用由双方共同承担，临床试验拟由阿斯利康发起。阿斯利康此次大额投资进一步验证了市场对该双特异性抗体商业潜力的认可，小摩与花旗亦对此投资表示看好。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Summit Therapeutics盘中大涨，阿斯利康注资20亿美元","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671321529","title":"阿斯利康(AZN.US)投资Summit(SMMT.US)获小摩与花旗看好：癌症药物策略迎验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2671321529","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671321529?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:52","pubTimestamp":1790679142,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1917777945.USD","LU0310800965.SGD","IXG","LU0265550359.USD","LU2505996681.GBP","LU1551013425.SGD","TRUF","UYG","LU1496350502.SGD","LU0234570918.USD","IYF","JPO","LU0320765489.SGD","LU0820561909.HKD","XLF","LU0314106906.USD","LU0215105999.USD","LU0211326839.USD","LU2505996509.AUD","TFNS","LU2237443382.USD","LU1670628061.USD","FTXO","JPMO","LU2430703251.USD","IE00BYXW3230.USD","LU1144417596.USD","LU1496350171.SGD","LU0345769631.USD","LU2168564149.EUR","VFH","LU1201861249.SGD","LU1074936037.SGD","LU0130517989.USD","IYG","LU0323591593.USD","IE00BDCRKT87.USD","KBWB","LU1894683264.USD","LU1791807156.HKD","LU0943347566.SGD","LU1244550221.USD","FNCL","LU0211331839.USD","LU0149725797.USD","LU2360032135.SGD","LU0942090050.USD","LU1244550494.USD","SMMT","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671949322","title":"纳微半导体美股盘前涨近13%，获得美国陆军拨款开发下一代10kV碳化硅功率半导体；生物制药公司SMMT大涨超23%，阿斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2671949322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671949322?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:03","pubTimestamp":1790669005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBP","IBBQ","SMMT","MRNX","LU2488822045.USD","STHH","BK4139","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186568791","title":"盘前异动 | 纳微半导体涨超12%，获美国陆军拨款开发半导体技术；Summit Therapeutics涨超23%，阿斯利康将向其投资20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186568791","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186568791?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:02","pubTimestamp":1790668966,"startTime":"0","endTime":"0","summary":"9月29日，美股三大股指期货涨跌不一，截止发稿，道指期货跌0.11%，纳指期货涨0.05%，标普500指数期货跌0.05%。热门中概股普跌，小鹏集团跌超3%，蔚来、理想汽车、携程网跌超2%，京东、百度、哔哩哔哩跌超1%；纳微半导体涨超12%，该公司获得美国陆军拨款开发碳化硅半导体技术；Summit Therapeutics涨超23%，阿斯利康将向其投资20亿美元，合作开发癌症药物；Faraday Future17%，机器人业务将估两亿美元上市，车业务升级为Robotaxi共享+AI视舱运营商；Fair Isaac跌超8%，信用评分垄断格局瓦解持续承压，多家投行近期密集下调目标价。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVTC","NVTX","SMMT","NVTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175292782","title":"异动解读｜Summit Therapeutics盘前上涨21.12%，阿斯利康20亿美元投资加码依沃西单抗合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1175292782","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175292782?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:00","pubTimestamp":1790668838,"startTime":"0","endTime":"0","summary":"9月29日，Summit Therapeutics盘前上涨21.12%，报19.00美元/股，成交额57.94万美元。消息面上，英国制药巨头阿斯利康宣布向Summit投资20亿美元可转换优先股，并达成一项围绕依沃西单抗的非约束性临床合作协议。双方计划评估依沃西单抗与阿斯利康旗下多款癌症药物的联合疗法，研究费用由双方共同承担，相关临床试验拟由阿斯利康发起。阿斯利康此次大额投资进一步验证了市场对该药物商业潜力的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"阿斯利康20亿美元加码，Summit盘前大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142524328","title":"美股夜盘｜Summit Therapeutics夜盘大升17%，纳微半导体升12%，Fair Isaac下跌9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142524328","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142524328?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:24","pubTimestamp":1790641445,"startTime":"0","endTime":"0","summary":"阿斯利康将向 Summit Therapeutics 投资 20 亿美元，合作开发癌症药物，后者夜盘大升 17%；纳微半导体获得美国陆军拨款开发半导体技术，股价夜盘大升 12%。AMD斥资82亿美元收购World Labs，李飞飞将加入AMD，出任执行副总裁兼首席科学家，AMD 夜盘微升； $Fair Isaac Corp$夜盘下跌 9%，此次下跌主要发生在美国联邦住房金融局采取相关措施之后。FHFA 计划采用统一定价表以及双评分体系，在房利美和房地美的各项机构业务中，将 VantageScore 与 FICO 信用评分同时纳入。","market":"us","thumbnail":"https://static.tigerbbs.com/1afea4c0436572ccffe9056dab1048f9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1afea4c0436572ccffe9056dab1048f9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVTS","SMMT","FICO","NVTC","NVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178138319","title":"异动解读｜Summit Therapeutics夜盘上涨17.96%，阿斯利康20亿美元投资加码依沃西单抗合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1178138319","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178138319?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:00","pubTimestamp":1790640046,"startTime":"0","endTime":"0","summary":"9月29日，Summit Therapeutics夜盘上涨17.96%，报18.26美元/股，成交额9130.0美元。消息面上，英国制药巨头阿斯利康宣布向Summit投资20亿美元可转换优先股，并达成一项围绕依沃西单抗的非约束性临床合作协议。双方计划评估依沃西单抗与阿斯利康旗下多款癌症药物的联合疗法，研究费用由双方共同承担。阿斯利康的大额投资进一步验证了市场对该双特异性抗体商业潜力的认可。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康20亿注资，Summit夜盘大涨","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265237","title":"据报道，Summit Therapeutics（SMMT）周一表示，英国制药公司阿斯利康（AstraZeneca，AZN","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671265237?lang=zh_cn&edition=full","pubTime":"2026-09-29 07:52","pubTimestamp":1790639529,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSKH","LENZ","BK4007","SMMT","LU2488822045.USD","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127495731","title":"阿斯利康将向 Summit Therapeutics 投资 20 亿美元，合作开发癌症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1127495731","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127495731?lang=zh_cn&edition=full","pubTime":"2026-09-29 07:48","pubTimestamp":1790639306,"startTime":"0","endTime":"0","summary":"Summit Therapeutics周一表示，英国制药公司阿斯利康将向该公司投资 20 亿美元，并合作开展一系列研究，测试双方的癌症治疗药物联合使用的效果。该消息公布后，Summit 股价在盘后交易中上涨超过 17%。此次投资体现了阿斯利康对 ivonescimab这一下一代癌症治疗药物的高度信心。Summit 此前从Akeso获得了该药物的授权。Ivonescimab 的作用机制是同时阻断 PD-1 和 VEGF。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康将向 Summit Therapeutics 投资 20 亿美元，合作开发癌症药物","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196458370","title":"异动解读｜Summit Therapeutics盘后上涨17.39%，多项重磅临床数据催化剂密集释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1196458370","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196458370?lang=zh_cn&edition=full","pubTime":"2026-09-29 05:31","pubTimestamp":1790631093,"startTime":"0","endTime":"0","summary":"9月29日，Summit Therapeutics盘后上涨17.39%，报18.17美元/股，成交额745.25万美元。消息面上，近期该公司核心药物依沃西单抗迎来多重催化剂。其合作方康方生物主导的III期HARMONi-GI1试验数据入选ESMO主席研讨会并将以LBA形式口头报告，该试验显示依沃西单抗联合化疗在一线治疗晚期胆道癌中总生存期显著优于阿斯利康度伐利尤单抗联合化疗方案。此外，WCLC大会更新的HARMONi-2研究数据显示，依沃西单抗单药对比帕博利珠单抗可降低27%死亡风险，且疗效在西方与亚洲患者中保持一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Summit盘后大涨，依沃西单抗多重数据催化","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165568594","title":"异动解读｜Summit Therapeutics盘中下跌5.03%，FDA审批不确定性持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1165568594","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165568594?lang=zh_cn&edition=full","pubTime":"2026-09-24 00:55","pubTimestamp":1790182552,"startTime":"0","endTime":"0","summary":"9月23日，Summit Therapeutics盘中下跌5.03%，报16.2593美元/股，成交额3472.72万美元。消息面上，尽管公司核心药物依沃西单抗近期在WCLC及ESMO等国际学术会议上密集披露积极临床数据，但市场焦点已转向FDA审批的不确定性。此前披露的HARMONi全球III期研究主要OS分析未达统计学显著性，而FDA曾明确指出该适应症需要统计学显著的OS获益，仅凭PFS数据可能不足以支持上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Summit股价下跌，FDA审批悬念压制市场","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199769998","title":"依沃西单抗联合化疗对比度伐利尤单抗联合化疗一线治疗晚期胆道癌中国患者——Harmoni-Gi1 III期临床研究入选ESMO 2026主席研讨会","url":"https://stock-news.laohu8.com/highlight/detail?id=1199769998","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199769998?lang=zh_cn&edition=full","pubTime":"2026-09-22 18:01","pubTimestamp":1790071305,"startTime":"0","endTime":"0","summary":"来自中国的Harmoni-Gi1研究即将在2026年欧洲肿瘤内科学会（ESMO）主席研讨会上惊艳亮相。这项III期临床试验聚焦于晚期胆道癌患者的一线治疗，核心比较对象为依沃西单抗（Ivonescimab）联合化疗方案与度伐利尤单抗（Durvalumab）联合化疗方案。这一重磅研究的入选，无疑为其在肿瘤学界的地位增添了浓墨重彩的一笔。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":-0.1683},{"period":"1month","weight":-0.1543},{"period":"3month","weight":0.0594},{"period":"6month","weight":-0.4183},{"period":"1year","weight":-0.3341},{"period":"ytd","weight":-0.1635}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Summit Therapeutics Inc.于2003年在英格兰和威尔士注册成立，特拉华州的一家公司（“New Summit”）已成为该公司的后续发行方。该公司是一家生物制药公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，旨在提高生活质量，延长潜在寿命，并解决严重的未满足的医疗需求。该公司的候选产品管线的设计目标是成为肿瘤治疗领域中对患者友好的、新时代的标准护理药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.0357},{"month":3,"riseRate":0.454545,"avgChangeRate":0.039344},{"month":4,"riseRate":0.5,"avgChangeRate":0.042597},{"month":5,"riseRate":0.5,"avgChangeRate":0.075963},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.093606},{"month":7,"riseRate":0.583333,"avgChangeRate":0.072153},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002579},{"month":9,"riseRate":0.416667,"avgChangeRate":0.08925},{"month":10,"riseRate":0.25,"avgChangeRate":-0.055114},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}